A detailed history of Vanguard Group Inc transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Vanguard Group Inc holds 1,928,078 shares of ENTA stock, worth $23.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,928,078
Previous 1,793,786 7.49%
Holding current value
$23.6 Million
Previous $16.9 Million 99.44%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$10.08 - $17.46 $1.35 Million - $2.34 Million
134,292 Added 7.49%
1,928,078 $33.7 Million
Q4 2023

Feb 14, 2024

BUY
$8.18 - $10.78 $1.09 Million - $1.44 Million
133,266 Added 8.03%
1,793,786 $16.9 Million
Q3 2023

Nov 14, 2023

SELL
$11.09 - $22.13 $506,313 - $1.01 Million
-45,655 Reduced 2.68%
1,660,520 $18.5 Million
Q2 2023

Aug 14, 2023

BUY
$20.68 - $39.85 $3.5 Million - $6.75 Million
169,272 Added 11.01%
1,706,175 $36.5 Million
Q1 2023

May 15, 2023

BUY
$38.82 - $54.59 $571,197 - $803,237
14,714 Added 0.97%
1,536,903 $62.2 Million
Q4 2022

Feb 10, 2023

BUY
$40.77 - $53.73 $1.85 Million - $2.43 Million
45,279 Added 3.07%
1,522,189 $70.8 Million
Q3 2022

Nov 14, 2022

SELL
$48.29 - $71.27 $1.92 Million - $2.84 Million
-39,779 Reduced 2.62%
1,476,910 $76.6 Million
Q2 2022

Aug 12, 2022

SELL
$38.13 - $76.93 $2.77 Million - $5.58 Million
-72,535 Reduced 4.56%
1,516,689 $71.7 Million
Q1 2022

May 13, 2022

SELL
$56.06 - $74.11 $2.06 Million - $2.72 Million
-36,685 Reduced 2.26%
1,589,224 $113 Million
Q4 2021

Feb 14, 2022

SELL
$60.19 - $97.37 $10.5 Million - $17 Million
-174,454 Reduced 9.69%
1,625,909 $122 Million
Q3 2021

Nov 12, 2021

SELL
$41.02 - $58.65 $2.32 Million - $3.32 Million
-56,656 Reduced 3.05%
1,800,363 $102 Million
Q2 2021

Aug 13, 2021

BUY
$43.76 - $53.11 $81.3 Million - $98.6 Million
1,857,019 New
1,857,019 $81.7 Million

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $254M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.